跨模态分割挑战赛揭示数据多样性如何提升肿瘤与耳蜗分割性能
crossMoDA Challenge: Evolution of Cross-Modality Domain Adaptation Techniques for Vestibular Schwannoma and Cochlea Segmentation from 2021 to 2023
- 用多机构、异构数据训练模型,提升跨模态医学图像分割鲁棒性
- 2023年优胜方案在旧数据上减少异常分割结果,证明数据多样性有益
- 适合医学影像算法研究者及临床辅助诊断系统开发者参考
跨模态域适应(crossMoDA)挑战赛自2021年起由MICCAI发起,聚焦于从增强T1(ceT1)图像无监督迁移至T2 MRI进行听神经瘤(VS)与耳蜗分割。该任务因模态间显著域偏移,成为评估跨模态泛化能力的理想基准。2021年仅使用单中心数据与基础分割;2022年引入多中心数据与Koos分级;2023年进一步纳入异构常规扫描数据,并要求区分肿瘤的颅内与颅外部分。本文报告2022与2023届成果并回顾挑战演进。分析显示,尽管数据扫描协议多样性上升,异常分割样本数量仍下降。2023年优胜方法在2021与2022测试集上显著减少异常结果,表明增加数据异质性可提升对同质数据的分割表现。但耳蜗Dice分数在2023年下降,可能源于肿瘤子区域标注带来的复杂性。尽管进展明显,当前性能仍未达临床可用标准,提示未来需设计更严苛的跨模态任务作为新基准。
原文摘要 · Abstract (English)
The cross-Modality Domain Adaptation (crossMoDA) challenge series, initiated in 2021 in conjunction with the International Conference on Medical Image Computing and Computer Assisted Intervention (MICCAI), focuses on unsupervised cross-modality segmentation, learning from contrast-enhanced T1 (ceT1) and transferring to T2 MRI. The task is an extreme example of domain shift chosen to serve as a meaningful and illustrative benchmark. From a clinical application perspective, it aims to automate Vestibular Schwannoma (VS) and cochlea segmentation on T2 scans for more cost-effective VS management. Over time, the challenge objectives have evolved to enhance its clinical relevance. The challenge evolved from using single-institutional data and basic segmentation in 2021 to incorporating multi-institutional data and Koos grading in 2022, and by 2023, it included heterogeneous routine data and sub-segmentation of intra- and extra-meatal tumour components. In this work, we report the findings of the 2022 and 2023 editions and perform a retrospective analysis of the challenge progression over the years. The observations from the successive challenge contributions indicate that the number of outliers decreases with an expanding dataset. This is notable since the diversity of scanning protocols of the datasets concurrently increased. The winning approach of the 2023 edition reduced the number of outliers on the 2021 and 2022 testing data, demonstrating how increased data heterogeneity can enhance segmentation performance even on homogeneous data. However, the cochlea Dice score declined in 2023, likely due to the added complexity from tumour sub-annotations affecting overall segmentation performance. While progress is still needed for clinically acceptable VS segmentation, the plateauing performance suggests that a more challenging cross-modal task may better serve future benchmarking.
Thank you to arXiv for use of its open access interoperability. PaperDance 不是 arXiv 官方产品;中文卡片由大模型生成,请以原文为准。